Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesDiseases and Disorders of the Hepatobiliary System and PancreasDRG 438-disorders-of-pancreas-except-malignancy-with-mcc
    Ask Trek AI about this page

    Disorders of Pancreas Except Malignancy with MCC: Inpatient Reimbursement Overview

    DRG 438 addresses nonmalignant pancreatic disorders with a Major Complication or Comorbidity, encompassing severe acute pancreatitis and related complex presentations that increase resource use. Correct assignment matters for inpatient reimbursement because the Major Complication or Comorbidity designation drives higher Medicare Severity Diagnosis-Related Group payment relative to less severe pancreatic diagnosis-related groups.

    Customize your policy alerts

    Sign up for drg 438 policy alerts

    Get alerted when payer policies referencing 438 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 438 Overview

    DRG 438 covers admissions for disorders of the pancreas except malignancy when a Major Complication or Comorbidity is present, such as severe pancreatitis with organ failure or significant systemic complications. These cases involve complex medical management and often require intensive resource use, including advanced imaging, endoscopic or surgical interventions, and prolonged inpatient care. Because the presence of a Major Complication or Comorbidity elevates the case severity, DRG 438 typically results in higher Medicare payment relative to lower-severity diagnosis-related groups for pancreatic conditions. Understanding this classification is important for accurate Medicare Severity Diagnosis-Related Group assignment and inpatient reimbursement.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Acute interventional trials evaluating minimally invasive or endoscopic approaches to manage severe pancreatitis complications (for example, randomized or prospective cohort studies comparing endoscopic transluminal drainage versus percutaneous drainage for infected pancreatic necrosis). These studies enroll hospitalized patients with severe non-malignant pancreatic disorders and major complications or organ failure and focus on short-term outcomes such as resolution of infection, need for surgery, organ support days, and in-hospital mortality. Results inform procedural choices, ICU resource utilization, and reimbursement considerations for high-cost acute care within this DRG.
    • Comparative effectiveness studies of inpatient medical management strategies for acute pancreatitis with major complications, comparing different fluid resuscitation protocols, nutrition routes (enteral vs. parenteral), or antibiotic stewardship approaches in real-world hospital populations. These trials or pragmatic observational studies target diverse adult inpatients with complicated pancreatitis to identify which care bundles reduce length of stay, intensive care utilization, and complication rates. Findings are directly relevant to clinicians optimizing evidence-based inpatient protocols and to payers evaluating cost-effectiveness and value-based payment models for DRG 438 admissions.
    • Post-discharge outcomes and readmission prevention studies assessing transitional care interventions, rehabilitation needs, and long-term pancreas insufficiency management after severe non-malignant pancreatic disease with major complications. These cohort studies or randomized trials enroll patients following hospital discharge and measure 30–90 day readmissions, development of chronic pancreatic insufficiency or diabetes, quality of life, and outpatient resource use. Understanding downstream morbidity and preventable readmissions helps providers plan discharge care and helps payers estimate longitudinal costs associated with this DRG.

    Related Codes

    405-PANCREAS-LIVER-AND-SHUNT-PROCEDURES-WITH-MCC

    Pancreas, Liver and Shunt Procedures with MCC: Inpatient Reimbursement Overview

    406-PANCREAS-LIVER-AND-SHUNT-PROCEDURES-WITH-CC

    Pancreas, Liver and Shunt Procedures with CC: Inpatient Reimbursement Overview

    407-PANCREAS-LIVER-AND-SHUNT-PROCEDURES-WITHOUT-CC-MCC

    Pancreas, Liver and Shunt Procedures without CC/MCC: Inpatient Reimbursement Overview

    408-BILIARY-TRACT-PROCEDURES-EXCEPT-ONLY-CHOLECYSTECTOMY-WITH-OR-WITHOUT-C-D-E-WITH-MCC

    Biliary Tract Procedures Except Only Cholecystectomy with or without C.D.E. with MCC: Inpatient Reimbursement Overview

    409-BILIARY-TRACT-PROCEDURES-EXCEPT-ONLY-CHOLECYSTECTOMY-WITH-OR-WITHOUT-C-D-E-WITH-CC

    Biliary Tract Procedures Except Only Cholecystectomy with or without C.D.E. with CC: Inpatient Reimbursement Overview

    410-BILIARY-TRACT-PROCEDURES-EXCEPT-ONLY-CHOLECYSTECTOMY-WITH-OR-WITHOUT-C-D-E-WITHOUT-CC-MCC

    Biliary Tract Procedures Except Only Cholecystectomy with or without C.D.E.: Inpatient Reimbursement Overview

    411-CHOLECYSTECTOMY-WITH-C-D-E-WITH-MCC

    Cholecystectomy with C.D.E. with MCC: Inpatient Reimbursement Overview

    412-CHOLECYSTECTOMY-WITH-C-D-E-WITH-CC

    Cholecystectomy with Common Duct Exploration with Complication or Comorbidity: Inpatient Reimbursement Overview

    413-CHOLECYSTECTOMY-WITH-C-D-E-WITHOUT-CC-MCC

    Cholecystectomy with C.D.E. without CC/MCC: Inpatient Reimbursement Overview

    414-CHOLECYSTECTOMY-EXCEPT-BY-LAPAROSCOPE-WITHOUT-C-D-E-WITH-MCC

    Cholecystectomy Except by Laparoscope without C.D.E. with MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 35

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.